ID   EW-18
AC   CVCL_1213
SY   EW18; IARC-EW-18
DR   CLO; CLO_0009870
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_1213
DR   Cell_Model_Passport; SIDM00197
DR   ChEMBL-Cells; CHEMBL3308832
DR   ChEMBL-Targets; CHEMBL2366097
DR   Cosmic; 684066
DR   Cosmic; 949164
DR   Cosmic; 1081697
DR   Cosmic; 1995402
DR   Cosmic; 2250476
DR   Cosmic-CLP; 949164
DR   DepMap; ACH-002115
DR   EGA; EGAS00001000978
DR   GDSC; 949164
DR   GEO; GSM1669786
DR   IARC_TP53; 27166
DR   LINCS_LDP; LCL-1450
DR   PharmacoDB; EW18_355_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1213
DR   Wikidata; Q54832995
RX   DOI=10.5282/edoc.27750;
RX   PubMed=20164919;
RX   PubMed=23637631;
RX   PubMed=25223734;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; HGNC:3508; EWSR1 + HGNC; HGNC:3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=23637631).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (PubMed=25223734).
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Proteomics; Quantitative.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; SNP array analysis.
CC   Genome ancestry: African=0%; Native American=0.97%; East Asian, North=0.41%; East Asian, South=0%; South Asian=0.22%; European, North=68.25%; European, South=30.15% (PubMed=30894373).
ST   Source(s): Cosmic-CLP=949164
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 10,13
ST   D16S539: 11,12
ST   D5S818: 11,12
ST   D7S820: 7,12
ST   TH01: 9.3
ST   TPOX: 8,11
ST   vWA: 16,17
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 35
//
RX   DOI=10.5282/edoc.27750;
RA   Orth M.F.;
RT   "Systematic multi-omics profiling of Ewing sarcoma cell lines.";
RL   Thesis PhD (2021); Ludwig Maximilians University of Munich; Munich; Germany.
//
RX   PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113;
RA   Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=23637631; DOI=10.1371/journal.pgen.1003464; PMCID=PMC3636093;
RA   Giacomini C.P., Sun S., Varma S., Shain A.H., Giacomini M.M.,
RA   Balagtas J.M.S., Sweeney R.T., Lai E., Del Vecchio C.A., Forster A.D.,
RA   Clarke N., Montgomery K.D., Zhu S., Wong A.J., van de Rijn M.,
RA   West R.B., Pollack J.R.;
RT   "Breakpoint analysis of transcriptional and genomic profiles uncovers
RT   novel gene fusions spanning multiple human cancer types.";
RL   PLoS Genet. 9:e1003464.1-e1003464.19(2013).
//
RX   PubMed=25223734; DOI=10.1158/2159-8290.CD-14-0622; PMCID=PMC4264969;
RA   Tirode F., Surdez D., Ma X.-T., Parker M., Le Deley M.-C., Bahrami A.,
RA   Zhang Z.-J., Lapouble E., Grossetete-Lalami S., Rusch M., Reynaud S.,
RA   Rio-Frio T., Hedlund E., Wu G., Chen X., Pierron G., Oberlin O.,
RA   Zaidi S., Lemmon G., Gupta P., Vadodaria B., Easton J., Gut M.,
RA   Ding L., Mardis E.R., Wilson R.K., Shurtleff S., Laurence V.,
RA   Michon J., Marec-Berard P., Gut I.G., Downing J.R., Dyer M.A.,
RA   Zhang J.-H., Delattre O.;
RG   International Cancer Genome Consortium;
RG   St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project;
RT   "Genomic landscape of Ewing sarcoma defines an aggressive subtype with
RT   co-association of STAG2 and TP53 mutations.";
RL   Cancer Discov. 4:1342-1353(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//